NYU researchers have identified the ELOVL1 enzyme as a critical regulator of neurotoxic reactive astrocytes that drive neuronal and oligodendrocyte death in various CNS diseases. By inhibiting ELOVL1, this therapeutic approach prevents the secretion of toxic long-chain lipids that cause lipoapoptosis. NYU is seeking partners to license and co-develop small-molecule ELOVL1 inhibitors as a first-in-class treatment for conditions including Alzheimer’s, Parkinson’s, ALS, multiple sclerosis, and acute CNS injuries.
This technology introduces a novel therapeutic approach to treat neurodegenerative diseases and acute central nervous system (CNS) injuries by targeting neurotoxic reactive astrocytes (NRAs). Researchers have discovered that these reactive astrocytes, which are prevalent in conditions such as Alzheimer’s, Parkinson’s, ALS, multiple sclerosis, and acute nerve trauma, secrete specific long-chain free fatty acids that cause lipoapoptosis—a form of programmed cell death—in neighboring neurons and oligodendrocytes. By inhibiting the ELOVL1 enzyme, which regulates the production of these toxic lipids, the technology offers a promising pathway to mitigate neuroinflammation and halt disease progression.
The primary therapeutic strategy involves the development of small-molecule inhibitors targeting ELOVL1, an elongase enzyme identified as the upstream regulator of the neurotoxic lipid synthesis pathway in astrocytes. Key features include:
The technology is at an early developmental stage, typically categorized as TRL 3-4. Researchers have successfully validated the mechanism in both in vitro and in vivo preclinical models, including acute axonal injury and chronic Alzheimer's Disease models, using...
New York University is a comprehensive private research university anchored in New York City, enrolling a large, diverse student body and operating a global network of campuses. Corporate engagement is enabled by co‑located engineering and computing hubs in Brooklyn and Manhattan with shared labs and facilities for prototyping and field pilots. Integration with a major hospital system supports clinical translation, IRB processes, and access to real‑world data under stringent governance. Proximity to leading industries and a mature sponsored‑research function streamline scoping, NDAs, MSAs, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DOD, and a dedicated technology transfer office manages IP, licensing, and startup creation.